Abstract 62 Table 1 Comparing patient characteristics between Caucasians and non-Caucasians

	Caucasian (n=30)	Non-Caucasians (n=53)	p-value
Socio-demographics			
Age, years, median [IQR]	48 [41-62]	39 [31-49]	0.002
≥College education,%	68	38	0.008
Disability,%	23	50	0.02
Marital status,%			
Single	10	42	0.002
Married	63	39	
Divorced	17	19	
Widowed	10	0	
Live with partner/spouse	70	48	0.05
Medicaid,%	10	25	0.09
Interpersonal Process of Care			
Hurried communication*, median [IQR]	1 [1-1.3]	1.3 [1-1.8]	0.001
Elicit concerns†, median [IQR]	5 [4.7-5]	5 [4.7-5]	0.6
Explained results†, median [IQR]	4.6 [3.6-5]	4.8 [4 - 5]	1
Patient-centered decision making†, median [IQR]	4.8 [3.8-5]	4.5 [3.8-5]	0.5
Compassionate respectful†, median [IQR]	5 [4.4-5]	5 [4.4-5]	0.7
Discrimination*, median [IQR]	1 [1 - 1]	1 [1 - 1]	0.2
Disrespectful office staff*, median [IQR]	1 [1 - 1]	1 [1 - 1]	0.8
Patient-reported Outcomes			
General Self-efficacy‡, median [IQR]	60 [49 - 65]	51 [42 - 62]	0.06
Self-efficacy in taking medications‡, median [IQR]	52 [43 - 61]	50 [42 - 54]	0.3
Fatigue‡, mean (SD)	58 (10)	54 (11)	0.06
Social health‡, mean (SD)	48 (10)	52 (10)	0.06
Clinical factors			
Years of diagnosis, median [IQR]	20 [7 - 26]	14 [8 - 17]	0.08
Rheumatic medication regimen complexity score, median [IQR]	5 [3 - 8]	8 [5 - 11]	0.004
SLICC damage score, median [IQR]	1 [0-2]	2 [1 - 3]	0.06
SLEDAI, median [IQR]	1 [0-4]	4 [1 - 8]	0.03
SLAQ, median [IQR]	11 [6 - 14]	9 [6 - 13]	0.7
Fibromyalgia symptom severity score, median [IQR]	4 (2)	3 (2)	0.04

IQR=interquartile range; SD=standard deviation; SLAQ=systemic lupus activity questionnaire; SLEDAI=systemic lupus erythematosus disease activity index; SLICC=systemic lupus international collaborating clinics

*Scores range from 1–5, with lower being better

†Scores range from 1–5, with higher being better

‡A score of 50 represents the US population mean, a difference in 5 is clinically significant. Higher scores are better for self-efficacy and social health, but lower scores are better for fatigue.

63

METABOLIC SYNDROME IN LUPUS AND RELATIONSHIP WITH THE NEUTROPHIL TO LYMPHOCYTE RATIO

Vanessa Castro*, Demelza D Yucra, Gabriela Garate, Hamaui Adriana, Diana Dubinsky. Sanatorio Guemes

10.1136/lupus-2019-lsm.63

Background In SLE there is five times more risk of cardiovascular events (CV) compared to the general population. In Argentina, a prevalence of metabolic syndrome (MetS) was reported in 28%. The SLICC cohort found 36.5% of MS in the first 2 years of diagnosis.

The neutrophil to lymphocyte ratio (NLR) is a marker of inflammation that relates the absolute count of neutrophils and lymphocytes, is a tool in the assessment of CV risk and systemic endothelial dysfunction. The NLR values reported in healthy is 1.65 (± 1.47). Studies in SLE show that NLR is a marker of activity and nephritis.

We aimed to determine the association of MetS with and without renal involvement, the relationship between NLR and MetS and relationship between NLR and disease activity.

Methods Descriptive, cross-sectional study.

Patients with SLE (SLICC 2012) of <5 years of evolution and >18 years followed at the Güemes Hospital were included, between 06/2013 to 07/2018.

Acute CV events, infections, pregnancy, diabetes and chronic kidney disease were excluded.

Risk factors nontraditional were determined: antiphospholipid (aPL), GC, SLEDAI.

MetS (NCEP ATP III criteria): Weight, height, abdominal perimeter (AP) and blood pressure.

PCR, neutrophil and lymphocyte count, glucose, CT, TG, LDL, urea, creatinine, proteinuria/24hs, Anti DNA, C3, C4, aPL: LA, Anti B2GP and Anti aCL antibody.

Statistical Analysis: Epi Info 7.2.0.

Results A total of 42 patients were reviewed, 12 were excluded (incomplete data).

Of 30 patients: 23 women (77%), mean age 39.3 ($\pm$ SD 14.3), evolution of disease: 35 months ($\pm$ SD 18.9), tobacco exposure: 11 (37%). Nephritis in 17 patients (51%).

MetS: 13 (43.3%), components: AP increased 15 (50%), HDL low 11 (37%), hypertension 11 (37%), high TG 8 (27%), hyperglycemia 3 (10%). Overweight: 17 (57%).

Mean BMI 27.4 ($\pm$ DS 6.2).

Characteristics of patients with and without MetS and relationship MetS and SLE with NLR. (Table).

Conclusions In our series, a greater frequency of MetS was found than literature. No relationship was found between MetS with renal involvement; however patients with MetS had higher proteinuria and elevated CRP.

No relationship was found between the NLR with MetS and nephritis. The NLR was higher in patients with SLEDAI 4.

The high prevalence of MetS, proteinuria, elevated CRP and NLR in our population suggest persistent inflammatory activity and probable CV morbidity, so it is important to detect it from the onset of the disease.

Funding Source(s): None

Funding Source(s): 5U54MD012530-02

Abstract 63 Table 1 Characteristics of patients with and without MetS and relationship MetS and SLE with NLR

	MetS n=13	Non MetS n=17	p
Female (%)	10 (77)	13 (76)	0.49
Age years (± SD)	38.6 (12.7)	40 (15.7)	0.62
Smoking exposure (%)	5 (38)	6 (35)	0.43
NLR (IQR)	3.42 (1.28-5.67)	3.05 (1-6)	0.52
BMI (± SD)	31 (7.2)	25 (4)	0.02
Nephritis (%)	7 (54)	10 (58)	0.39
Proteinuria gr/24 hrs (± SD)	1.5 (3.19)	0.35 (0.54)	0.03
Class III / IV	4/7 (57)	6/10 (60)	0.45
CRP mg/dl (± SD)	8.7 (10)	7.61 (22)	0.02
aPL + (%)	6 (46)	4 (23)	0.11
SLEDAI (± SD)	2.8 (3.5)	2.4 (2.52)	0.74
SLICC (± SD)	0.23 (0.43)	0.23 (0.43)	0.97
Accumulated corticoid gr (± SD)	6.74 (4.6)	9.43 (5.9)	0.25
HCC (%)	12 (92)	17 (100)	0.21
ASA (%)	3 (23)	4 (24)	0.49
	NLR (±DS)	p	
MetS	3.42 (1.32)	0.52	
MetS ≥4 criteria	3.77 (3.77)	0.61	
Nephritis	3.35 (1.62)	0.67	
SLEDAI ≥ 4	4.43 (1.42)	0.027	
CRP > 5	3.87 (1.50)	0.11	

64

ANA BY INDIRECT IMMUNOFLUORESCENCE ALONE RARE IN SLE AND CLINICAL PHENOTYPE OF PATIENTS WITH ANA PLUS LUPUS ASSOCIATED ANTIBODIES IS DIFFERENT THAN ANA ALONE

H Michael Belmont*, Peter Izmirly, Jill Buyonm. NYU School of Medicine

10.1136/lupus-2019-lsm.64

Background Autoantibody and laboratory testing is essential for SLE diagnosis. ANA by indirect immunofluorescence (ANA IIF) remains the gold standard to screen for lupus and studies demonstrate preclinical phase during which autoantibodies accumulate. Prevalence of ANA IIF alone without more specific autoantibodies and the accompanying clinical phenotype of these patients uncertain.

Methods Queried 602 patients in the NYU Lupus Registry with 4 or more ACR or SLICC criteria as adjudicated by the authors for prevalence of ANA IIF, dsDNA, Sm, Ro, La, RNP, aPL, C3, C4. Compared clinical features of isolated ANA (ANA IIF alone) with the ANA IIF plus one or more lupus associated abnormalities (ANA IIF +).

Results 590/602 (98%) ANA IIF positive. 548/590 (93%) patients at least one of associated tests compared to only 42/590 (7%) ANA IIF alone. SLE nephritis significantly more prevalent in ANA IIF+254/548 (46%), compared to 13/42 (31%) recorded with renal criteria ANA IIF alone. ANA IIF +, 158/254 (62%) biopsy proven nephritis (LN), rather than relying on proteinuria for diagnosis, compared to 5/13 (38%) of ANA IIF alone biopsy proven LN. Remaining 8 ANA IIF alone, uPCR exceeded 0.5 g in 1 of 44 (2%) encounters. Low incidence of proteinuria explained by complete renal response or prior proteinuria misconstrued as evidence of LN. In comparison, uPCR >0.5 g was present in 694 of 1157 (60%) encounters in ANA IIF +, casting doubt on validity of LN diagnosis in 8 ANA IIF alone without biopsy.

Leucopenia, lymphocytopenia, AITP, AIHA statistically less ANA IIF alone compared to ANA IIF + ; 24% vs 36%, 29% vs 40%, 7% vs 15% and 0% vs 7%, respectively. 42 patients with ANA IIF alone prevalence of potentially misattributed (e.g. not result of IMID) clinical criteria such as photosensitivity (64%) and malar rash (60%) greater compared to ANA IIF +, 38% and 44%, respectively. Prevalence oral ulcers, DLE, arthritis, serositis, seizures and psychosis equivalent in both.

Abstract 64 Table 1

	ANA IIF +	ANA IIF alone	P Value
n	548/590 (93%)	42/590 (7%)	<0.001
Nephritis	254/548 (46%)	13/42 (31%)	=0.0442
GN by biopsy	158/254 (62%)	5/13 (38%)	=0.1222
GN by proteinuria	96/254 (38%)	8/13 (62%)	=0.1222
Visits with uPCR>0.5 (60%)	694/1157	1/44 (2%)	<0.0001
Malar rash	44%	60%	=0.1163
Photosensitivity	38%	64%	=0.0018
AITP	15%	7%	=0.0544
AIHA	7%	0%	<0.0001
Leucopenia	36%	24%	=0.0254
Lymphocytopenia	40%	29%	=0.0888
Oral ulcers	24%	26%	NS
DLE	22%	33%	NS
Arthritis	70%	69%	NS
Serositis	27%	31%	NS
Seizures	4%	2%	NS
Psychosis	2%	5%	NS

ACR Clinical Criteria ANA IIF alone vs ANA IIF +